QUEBEC, QC--(Marketwired - November 30, 2017) - The Hydropothecary Corporation ("Hydropothecary" or the "Company") (TSX VENTURE: THCX) participated in the Quebec government's consultations on Bill 157, the proposed law governing the production and distribution of recreational cannabis in the province.

During its historic presentation to the Health and Social Services Committee of the National Assembly, the Company signaled its support for the proposed legislation, calling for changes that would help protect the health and safety of Quebecers, counter the province's black market for cannabis and create jobs and economic opportunity for communities across the province.

"As the first licensed producer of medical cannabis in the province of Quebec and the only licensed producer headquartered in the province, Hydropothecary is honoured to reinforce its focus on protecting the public health and safety of Quebecers and keeping legal cannabis out of the hands of children," noted Hydropothecary's Co-founder and CEO Sébastien St-Louis. "Hydropothecary's growing, product manufacturing and quality assurance processes will ensure that Quebecers will have access to safe regulated innovative recreational cannabis products that adhere to international pharmacopoeia standard used to control, potency, purity, and quality".

Mr. St-Louis also commented on the substantial job creation and business opportunities in recreational cannabis for the province. Quebec's recreational cannabis market is estimated to be in the range of $1.3 billion per year.

"In the last year Hydropothecary has doubled its number of employees. There are approximately one hundred people who come to our Gatineau facility every day to earn a living," noted Mr. St-Louis. "With the new micro-cultivator and micro-processor licenses coming, Quebec has the opportunity to create thousands of jobs in small and medium-sized communities across the province and Quebec can count on Hydropothecary to help" commented Mr. St-Louis.

The presentation ended with an acknowledgement of Hydropothecary's social responsibility to the Province. "We have a tremendous opportunity with cannabis in the province of Quebec. We want to let Quebecers now we understand that with opportunity comes tremendous social responsibility," concluded Mr. St- Louis.

Please note that a version of the brief is posted online at

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

About Hydropothecary Corporation (THCX)

The Hydropothecary Corporation is an authorized licensed producer and distributor of medical cannabis licensed by Health Canada under the Access to Cannabis for Medical Purposes Regulations (Canada). Hydropothecary provides naturally grown and rigorously tested medical cannabis of uncompromising quality. Hydropothecary's branding, cannabis product offering, patient service standards and product pricing are consistent with THCX's positioning as a premium brand for a legal source for medical cannabis within this new marketplace. In addition to medical cannabis production and sales, Hydropothecary explores various research and development opportunities for cannabinoid extracts, drugs and combinatory chemistry. In addition, the company is investigating the development and patenting of novel technologies related to medical cannabis, as well as the import and export of medical cannabis.

Contact Information:

Contact Information

Media Contact Information
Julie Beun
Publicity and Media Relations

Investor Relations Contact Information
Jennifer Smith
Manager of Financial Reporting and Investor Relations
1-866-438-THCX (8429)

Adam Miron